A Randomized, Parallel Group, Multiple Dose, 6-Week Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Asenapine in Elderly Subjects With Psychosis.

Trial Profile

A Randomized, Parallel Group, Multiple Dose, 6-Week Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Asenapine in Elderly Subjects With Psychosis.

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Jun 2014

At a glance

  • Drugs Asenapine (Primary)
  • Indications Psychotic disorders
  • Focus Adverse reactions; Pharmacokinetics; Registrational
  • Sponsors Merck Sharp & Dohme; Organon; Pfizer
  • Most Recent Events

    • 01 Sep 2010 Results were reported at the 23rd Annual Congress of the European College of Neuropsychopharmacology.
    • 27 May 2010 Tolerability and pharmacokinetic outcomes were reported at the 163rd Annual Meeting of the American Psychiatric Association.
    • 13 Oct 2009 Schering-Plough added instead of Organon as Organon was taken over by Schering-Plough.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top